CS
Chirag Singhal's blog
Health & Medicine · 3 min read

Summary: Pregnancy, Teratogenicity, and Lactation Risks

A critical comparison of how Bipolar Disorder medications affect pregnancy, fetal development, and breastfeeding, highlighting the severe dangers of Valproate.

Summary: Pregnancy, Teratogenicity, and Lactation Risks

Treating Bipolar Disorder during pregnancy is one of the most difficult challenges in psychiatry. A severe manic or depressive episode is dangerous for both mother and fetus, but many psychiatric drugs cause severe birth defects.


1. Sodium Valproate (Extreme Danger - Category X/D)

  • The Risk: Sodium Valproate is highly teratogenic. It carries a Black Box Warning for causing severe birth defects, primarily neural tube defects like spina bifida. The risk is up to 20 times higher than in the general population.
  • Long-Term Impact: Infants exposed in the womb have a statistically significant risk of lower IQs and developing Autism Spectrum Disorders.
  • Guidance: It must be absolutely avoided in women of childbearing age unless there is no alternative and strict contraception is used.

2. Lorazepam (High Risk - Category D)

  • The Risk: Benzodiazepines cross the placenta. Use during the first trimester increases the risk of congenital malformations (like cleft lip).
  • Third Trimester Danger: If used late in pregnancy, it causes “Floppy Infant Syndrome.” The newborn is born with severe muscle weakness, hypothermia, and life-threatening respiratory depression.
  • Breastfeeding: It is excreted in breast milk and will cause severe lethargy and weight loss in the nursing infant.

3. Escitalopram (Moderate Risk - Category C)

  • The Risk: While safer than Valproate, Escitalopram carries specific risks in the third trimester. It can cause Persistent Pulmonary Hypertension of the Newborn (PPHN), a severe breathing condition.
  • Neonatal Withdrawal: Babies born to mothers on SSRIs often experience a withdrawal syndrome—they are born jittery, crying constantly, and have feeding difficulties.

4. Olanzapine (Moderate Risk - Category C)

  • The Risk: There is no definitive proof of structural birth defects, but the massive weight gain and risk of gestational diabetes caused by Olanzapine heavily complicate the pregnancy.
  • Neonatal Impact: Neonates exposed in the third trimester are at risk for extrapyramidal symptoms (muscle stiffness, tremors) and withdrawal symptoms following delivery.

5. Propranolol (Moderate Risk - Category C)

  • The Risk: Propranolol crosses the placenta. Because it lowers heart rate and blood pressure, it can cause the fetus to experience bradycardia (slow heart rate) and hypoglycemia (low blood sugar) at birth.
  • Guidance: Used only if the benefit to the mother’s cardiovascular system outweighs the risk to the fetus. The newborn must be heavily monitored for blood sugar crashes.

Return to Index: The Comprehensive Bipolar Disorder Medicines Guide

Share:
Bookmark

Comments

Related Posts